EBP1 protein modulates the expression of human MHC class II molecules in non-hematopoietic cancer cells

Pisapia,Laura; Barba,Pasquale; Cortese,Angela; Cicatiello,Valeria; Morelli,Franco; Del Pozzo,Giovanna

doi:10.3892/ijo.2015.3051

EBP1 protein modulates the expression of human MHC class II molecules in non-hematopoietic cancer cells

Authors:
- Laura Pisapia
- Pasquale Barba
- Angela Cortese
- Valeria Cicatiello
- Franco Morelli
- Giovanna Del Pozzo
View Affiliations

Affiliations: Institute of Genetics and Biophysics ‘Adriano Buzzati Traverso’-CNR, 80131 Naples, Italy
Published online on: June 16, 2015 https://doi.org/10.3892/ijo.2015.3051
Pages: 481-489
Copyright: © Pisapia et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Many solid tumours including melanoma, glioblastoma, and breast carcinomas express MHC class II molecules (MHC II). The surface expression of these molecules confers to non-hematopoietic tumour cells the role of non-professional antigen presenting cells and the ability to potentially stimulate tumour-specific CD4+ T cell response. We studied EBP1, an ErbB3 binding protein, and the effects of p48 and p42 isoforms on the MHC II expression in U87 glioblastoma, M14 melanoma and MCF7 mammary carcinoma cell lines. We found that overexpression of p48 increases MHC II transcription in U87 and M14, through upregulation of CIITA transactivator and STAT1 phosphorylation. In addition, p48 protein influences MHC II expression by increasing mRNA stability. In melanoma and glioblastoma cell lines, p48 isoform functions as oncogene promoting tumour growth, while p42 isoform, that does not affect MHC II expression, acts as a tumour suppressor by blocking cell growth and inducing apoptosis. In contrast, p48 seems to act as tumour suppressor in breast carcinoma inhibiting proliferation, favouring apoptosis, and inducing a slight increase of MHC II expression similar to p42. Our data highlight the tissue specificity function of EBP1 isoforms and demonstrate that only the oncogene p48 activates MHC II expression in human solid tumours, via STAT1 phosphorylation, in order to affect tumour progression by triggering specific immune response.

View Figures

View References

1	Kobayashi H and Celis E: Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol. 20:221–227. 2008. View Article : Google Scholar : PubMed/NCBI
2	Campoli M and Ferrone S: HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance. Oncogene. 27:5869–5885. 2008. View Article : Google Scholar : PubMed/NCBI
3	Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, et al: How do CD4⁺ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front Immunol. 5:1742014. View Article : Google Scholar
4	Reith W, LeibundGut-Landmann S and Waldburger JM: Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol. 5:793–806. 2005. View Article : Google Scholar : PubMed/NCBI
5	Pisapia L, Pozzo GD, Barba P, Citro A, Harris PE and Maffei A: Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter. Results Immunol. 2:174–183. 2012. View Article : Google Scholar
6	Ting JP and Trowsdale J: Genetic control of MHC class II expression. Cell. 109(Suppl): S21–S33. 2002. View Article : Google Scholar : PubMed/NCBI
7	Pisapia L, Cicatiello V, Barba P, Malanga D, Maffei A, Hamilton RS and Del Pozzo G: Co-regulated expression of alpha and beta mRNAs encoding HLA-DR surface heterodimers is mediated by the MHCII RNA operon. Nucleic Acids Res. 41:3772–3786. 2013. View Article : Google Scholar : PubMed/NCBI
8	Corso C, Pisapia L, Citro A, Cicatiello V, Barba P, Cigliano L, Abrescia P, Maffei A, Manco G and Del Pozzo G: EBP1 and DRBP76/NF90 binding proteins are included in the major histocompatibility complex class II RNA operon. Nucleic Acids Res. 39:7263–7275. 2011. View Article : Google Scholar : PubMed/NCBI
9	Xia X, Lessor TJ, Zhang Y, Woodford N and Hamburger AW: Analysis of the expression pattern of Ebp1, an ErbB-3-binding protein. Biochem Biophys Res Commun. 289:240–244. 2001. View Article : Google Scholar : PubMed/NCBI
10	Lessor TJ, Yoo JY, Xia X, Woodford N and Hamburger AW: Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines. J Cell Physiol. 183:321–329. 2000. View Article : Google Scholar : PubMed/NCBI
11	Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A and Hamburger AW: The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci USA. 102:9890–9895. 2005. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Linn D, Liu Z, Melamed J, Tavora F, Young CY, Burger AM and Hamburger AW: EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther. 7:3176–3186. 2008. View Article : Google Scholar : PubMed/NCBI
13	Zhang Y, Ali TZ, Zhou H, D’Souza DR, Lu Y, Jaffe J, Liu Z, Passaniti A and Hamburger AW: ErbB3 binding protein 1 represses metastasis-promoting gene anterior gradient protein 2 in prostate cancer. Cancer Res. 70:240–248. 2010. View Article : Google Scholar : PubMed/NCBI
14	Zhang Y, Woodford N, Xia X and Hamburger AW: Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases. Nucleic Acids Res. 31:2168–2177. 2003. View Article : Google Scholar : PubMed/NCBI
15	Zhang Y and Hamburger AW: Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling. Br J Cancer. 92:140–146. 2005. View Article : Google Scholar
16	Sun J, Luo Y, Tian Z, Gu L, Xia SC and Yu Y: Expression of ERBB3 binding protein 1 (EBP1) in salivary adenoid cystic carcinoma and its clinicopathological relevance. BMC Cancer. 12:4992012. View Article : Google Scholar : PubMed/NCBI
17	Zhou X, Chen W, Zhang Y, Sun J, Wang Q and Yu Y: Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer. J Cancer Res Clin Oncol. 136:891–896. 2010. View Article : Google Scholar
18	He HC, Ling XH, Zhu JG, Fu X, Han ZD, Liang YX, Deng YH, Lin ZY, Chen G, Chen YF, et al: Down-regulation of the ErbB3 binding protein 1 in human bladder cancer promotes tumor progression and cell proliferation. Mol Biol Rep. 40:3799–3805. 2013. View Article : Google Scholar : PubMed/NCBI
19	Hu B, Xiong Y, Ni R, Wei L, Jiang D, Wang G, Wu D, Xu T, Zhao F, Zhu M, et al: The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Mol Cell Biochem. 396:175–185. 2014. View Article : Google Scholar : PubMed/NCBI
20	Liu Z, Ahn JY, Liu X and Ye K: Ebp1 isoforms distinctively regulate cell survival and differentiation. Proc Natl Acad Sci USA. 103:10917–10922. 2006. View Article : Google Scholar : PubMed/NCBI
21	Kim CK, Nguyen TL, Joo KM, Nam DH, Park J, Lee KH, Cho SW and Ahn JY: Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Cancer Res. 70:9730–9741. 2010. View Article : Google Scholar : PubMed/NCBI
22	Bose SK, Sengupta TK, Bandyopadhyay S and Spicer EK: Identification of Ebp1 as a component of cytoplasmic bcl-2 mRNP (messenger ribonucleoprotein particle) complexes. Biochem J. 396:99–107. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zhou H, Mazan-Mamczarz K, Martindale JL, Barker A, Liu Z, Gorospe M, Leedman PJ, Gartenhaus RB, Hamburger AW and Zhang Y: Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer. Nucleic Acids Res. 38:3619–3631. 2010. View Article : Google Scholar : PubMed/NCBI
24	Zhou H, Zhang Y and Hamburger AW: EBP1 inhibits translation of androgen receptor mRNA in castration resistant prostate cancer cells. Anticancer Res. 31:3129–3135. 2011.PubMed/NCBI
25	Squatrito M, Mancino M, Donzelli M, Areces LB and Draetta GF: EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. Oncogene. 23:4454–4465. 2004. View Article : Google Scholar : PubMed/NCBI
26	Squatrito M, Mancino M, Sala L and Draetta GF: Ebp1 is a dsRNA-binding protein associated with ribosomes that modulates eIF2alpha phosphorylation. Biochem Biophys Res Commun. 344:859–868. 2006. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
28	Zhang Y, Akinmade D and Hamburger AW: Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1. Cancer Lett. 265:298–306. 2008. View Article : Google Scholar : PubMed/NCBI
29	Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP and Antony PA: Naive tumor-specific CD4⁺ T cells differentiated in vivo eradicate established melanoma. J Exp Med. 207:651–667. 2010. View Article : Google Scholar : PubMed/NCBI
30	Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, Blasberg R, Yagita H, Muranski P, Antony PA, et al: Tumor-reactive CD4⁺ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 207:637–650. 2010. View Article : Google Scholar : PubMed/NCBI
31	Thibodeau J, Bourgeois-Daigneault MC and Lapointe R: Targeting the MHC class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology. 1:908–916. 2012. View Article : Google Scholar : PubMed/NCBI
32	Holling TM, van Eggermond MC, Jager MJ and van den Elsen PJ: Epigenetic silencing of MHC2TA transcription in cancer. Biochem Pharmacol. 72:1570–1576. 2006. View Article : Google Scholar : PubMed/NCBI
33	Zhang Y, Fondell JD, Wang Q, Xia X, Cheng A, Lu ML and Hamburger AW: Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1. Oncogene. 21:5609–5618. 2002. View Article : Google Scholar : PubMed/NCBI
34	Zhang Y, Akinmade D and Hamburger AW: The ErbB3 binding protein Ebp1 interacts with Sin3A to repress E2F1 and AR-mediated transcription. Nucleic Acids Res. 33:6024–6033. 2005. View Article : Google Scholar : PubMed/NCBI
35	Xia X, Cheng A, Lessor T, Zhang Y and Hamburger AW: Ebp1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation. J Cell Physiol. 187:209–217. 2001. View Article : Google Scholar : PubMed/NCBI
36	Kim CK, Lee SB, Nguyen TL, Lee KH, Um SH, Kim J and Ahn JY: Long isoform of ErbB3 binding protein, p48, mediates protein kinase B/Akt-dependent HDM2 stabilization and nuclear localization. Exp Cell Res. 318:136–143. 2012. View Article : Google Scholar
37	Liu Z, Oh SM, Okada M, Liu X, Cheng D, Peng J, Brat DJ, Sun SY, Zhou W, Gu W, et al: Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Mol Biol Cell. 20:757–768. 2009. View Article : Google Scholar :
38	Kwon IS and Ahn JY: p48 Ebp1 acts as a downstream mediator of Trk signaling in neurons, contributing neuronal differentiation. Neurochem Int. 58:215–223. 2011. View Article : Google Scholar
39	Monie TP, Perrin AJ, Birtley JR, Sweeney TR, Karakasiliotis I, Chaudhry Y, Roberts LO, Matthews S, Goodfellow IG and Curry S: Structural insights into the transcriptional and translational roles of Ebp1. EMBO J. 26:3936–3944. 2007. View Article : Google Scholar : PubMed/NCBI
40	Yap DB, Hsieh JK, Chan FS and Lu X: mdm2: A bridge over the two tumour suppressors, p53 and Rb. Oncogene. 18:7681–7689. 1999. View Article : Google Scholar